Book contents
- Frontmatter
- Contents
- List of contributors
- Preface
- Part I Introduction: definition and classification of the human herpesviruses
- Part II Basic virology and viral gene effects on host cell functions: alphaherpesviruses
- Part II Basic virology and viral gene effects on host cell functions: betaherpesviruses
- Part II Basic virology and viral gene effects on host cell functions: gammaherpesviruses
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HSV-1 and HSV-2
- Part III Pathogenesis, clinical disease, host response, and epidemiology: VZU
- 37 VZV: pathogenesis and the disease consequences of primary infection
- 38 VZV: molecular basis of persistence (latency and reactivation)
- 39 VZV: immunobiology and host response
- 40 VZV: persistence in the population: transmission and epidemiology
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HCMV
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HHV- 6A, 6B, and 7
- Part III Pathogenesis, clinical disease, host response, and epidemiology: gammaherpesviruses
- Part IV Non-human primate herpesviruses
- Part V Subversion of adaptive immunity
- Part VI Antiviral therapy
- Part VII Vaccines and immunothgerapy
- Part VIII Herpes as therapeutic agents
- Index
- Plate section
- References
40 - VZV: persistence in the population: transmission and epidemiology
from Part III - Pathogenesis, clinical disease, host response, and epidemiology: VZU
Published online by Cambridge University Press: 24 December 2009
- Frontmatter
- Contents
- List of contributors
- Preface
- Part I Introduction: definition and classification of the human herpesviruses
- Part II Basic virology and viral gene effects on host cell functions: alphaherpesviruses
- Part II Basic virology and viral gene effects on host cell functions: betaherpesviruses
- Part II Basic virology and viral gene effects on host cell functions: gammaherpesviruses
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HSV-1 and HSV-2
- Part III Pathogenesis, clinical disease, host response, and epidemiology: VZU
- 37 VZV: pathogenesis and the disease consequences of primary infection
- 38 VZV: molecular basis of persistence (latency and reactivation)
- 39 VZV: immunobiology and host response
- 40 VZV: persistence in the population: transmission and epidemiology
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HCMV
- Part III Pathogenesis, clinical disease, host response, and epidemiology: HHV- 6A, 6B, and 7
- Part III Pathogenesis, clinical disease, host response, and epidemiology: gammaherpesviruses
- Part IV Non-human primate herpesviruses
- Part V Subversion of adaptive immunity
- Part VI Antiviral therapy
- Part VII Vaccines and immunothgerapy
- Part VIII Herpes as therapeutic agents
- Index
- Plate section
- References
Summary
Like other herpes viruses, varicella zoster virus (VZV) causes disease due to the primary infection (varicella) and due to reactivation (herpes zoster). However, VZV differs from other herpes viruses in causing primary and reactivation infections that are easily recognized clinical diseases, even by the lay public. Because of this, the epidemiology of varicella and herpes zoster has been well described from clinically recognized disease (incidence, severe disease outcomes and deaths) with seroprevalence data providing additional information on the epidemiology of varicella especially in populations where varicella disease history may not be available.
Varicella occurs worldwide with ongoing endemic transmission in areas where populations are sufficiently large to support such transmission. However the epidemiology of varicella varies between temperate and tropical climates (Lee, 1998). Universal childhood vaccination programs have changed the epidemiology of varicella in countries implementing such programs with significant declines in disease. Most experience has been gained in the United States where a varicella vaccination program was initiated in 1995. Herpes zoster infections also occur throughout the world although the epidemiology of herpes zoster is less well described globally. Because the incidence of herpes zoster increases dramatically with age, countries with lower life expectancies may have lower health burdens due to this disease. A vaccine for prevention of herpes zoster and post-herpetic neuralgia was licensed in the USA in May, 2006 (Oxman et al., 2005). This chapter reviews pre- and post-vaccine epidemiology of varicella and herpes zoster.
- Type
- Chapter
- Information
- Human HerpesvirusesBiology, Therapy, and Immunoprophylaxis, pp. 713 - 734Publisher: Cambridge University PressPrint publication year: 2007
References
- 10
- Cited by